| The molecule has been isolated from Indian medicinal plants and is claimed to be more effective than the existing anti-ulcer drugs. |
| "We have crossed the preliminary stage of isolating the new chemical entity. It is ready for pre-clinical toxicology studies. We are in discussions with the industry and it is likely to enter the market within three years. The global market for this drug is likely to be over $5 billion," JS Yadav, director of IICT, told mediapersons. The institute will be celebrating its 62nd Foundation Day on August 5, 2006. |
| The molecule has been code-named OA-5 and it has showed potent antigastric ulcer activity against ulcers that are chemical induced, stress induced, pylorus ligated and ethanol induced. |
| However, it is not effective against H Pylori induced ulcers. IICT has filed 104 patents (75 overseas) and has been granted 64 patents (33 overseas). |
| Meanwhile, IICT is also setting up a Centre for Combinatorial Natural Products at an investment of Rs 25 crore for drug development from plant products. |
| This is likely to be ready within a year. The institute's plan to set up a biotechnology incubator in Andhra Pradesh since 2003 has not borne fruits because of lack of monetary support, according to Yadav. |
| "The department of biotechnology has replied positively to our request for funds. We are still awaiting sanction," he added. The total external cash flow (ECF) of IICT for 2005-06 was Rs 25.2 crore with the ECF from the industry being Rs 8.6 crore. |
| Q&A with JS Yadav, director, IICT: https://www.business-standard.com/search/storypage_new.php?leftnm=1&leftindx=1&subLeft=2&autono=216123 |
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
